Cargando…

Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin

Direct oral anticoagulants (DOACs) are becoming increasingly prevalent in the general population for anticoagulation. However, rare adverse effects from these medications are still being discovered. Thrombocytopenia has previously been reported with these medications, but its clinical significance i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tucker, Madeline, Padarti, Akhil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592300/ https://www.ncbi.nlm.nih.gov/pubmed/34804643 http://dx.doi.org/10.7759/cureus.18757

Ejemplares similares

Comparative Efficacy of Direct Oral Anticoagulants and Low-Molecular-Weight Heparin in Cancer-Associated Thromboembolism: A Systematic Review and Meta-Analysis
por: Patel, Tirath, et al.
Publicado: (2023)

Direct Oral Anticoagulants as Successful Treatment of Heparin-Induced Thrombocytopenia: A Parisian Retrospective Case Series
por: Carré, Julie, et al.
Publicado: (2021)

The Role of Apixaban in the Treatment of Heparin-Induced Thrombocytopenia
por: Khalid, Sidra, et al.
Publicado: (2017)

Heparin-induced Thrombocytopenia: Pathophysiology, Diagnosis and Management
por: Patriarcheas, Vasileios, et al.
Publicado: (2020)

The Appropriateness of Testing Platelet Factor 4/Heparin Antibody in Patients Suspected of Heparin-induced Thrombocytopenia
por: Jindal, Vishal, et al.
Publicado: (2018)

Is COVID-19 an Independent Risk Factor for Heparin-Induced Thrombocytopenia?
por: Madala, Samragnyi, et al.
Publicado: (2021)

Beware of Warfarin-Induced Skin Necrosis in the Setting of Heparin-Induced Thrombocytopenia
por: Dhawan, Natasha
Publicado: (2020)

Extensive Thrombosis in a Severe COVID-19 Patient Despite Prophylactic Low Molecular Weight Heparin
por: Elkattawy, Sherif, et al.
Publicado: (2020)

The Safety and Efficacy of Low-Molecular-Weight Heparin in Pregnant Women With Rheumatic Heart Disease and Valves Replacement
por: Alghamdi, Najwa, et al.
Publicado: (2022)

Acute Levetiracetam-Induced Thrombocytopenia in an Anticoagulated Immunocompetent Patient
por: Nwaedozie, Somto T, et al.
Publicado: (2021)

Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis
por: Palamaner Subash Shantha, Ghanshyam, et al.
Publicado: (2015)

Comparison of the Efficacy and Safety of Aspirin and Low-Molecular-Weight Heparin in Patients With a Fracture: A Meta-Analysis
por: Nimerta, FNU, et al.
Publicado: (2023)

Early Utilization of Intravenous Immunoglobulin in Heparin-Induced Thrombocytopenia for Limb Salvaging Purposes
por: Abu Kar, Sarah, et al.
Publicado: (2022)

Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome
por: Arora, Shreya, et al.
Publicado: (2021)

Upper Limb Phlegmasia Cerulea Dolens Secondary to Heparin-induced Thrombocytopenia Leading to Gangrene
por: Kommalapati, Anuhya, et al.
Publicado: (2018)

Heparin/low molecular weight heparins: Thrombocytopenia: 7 case reports
Publicado: (2021)

Autoimmune Heparin-Induced Thrombocytopenia: A Diagnostic and Management Challenge After Transcatheter Aortic Valve Replacement
por: Batool, Aisha, et al.
Publicado: (2023)

Type II Heparin-Induced Thrombocytopenia: An Underrecognized Cause of Dialysis Catheter Dysfunction - A Case Report
por: Karki, Sailesh, et al.
Publicado: (2023)

Drug Use Evaluation of Direct Oral Anticoagulants (DOACs) in Patients With Advanced Cirrhosis
por: Jarboe, Lindsey, et al.
Publicado: (2022)

Low-molecular weight heparin infusion as anticoagulation for haemodialysis
por: Wong, Steve Siu-Man, et al.
Publicado: (2016)

Non-Traumatic Intramuscular Hip Hematoma in a Cirrhotic Patient With Hepatocellular Carcinoma and Portal Vein Thrombosis Treated With Sorafenib and Low Molecular Weight Heparin
por: Sotiropoulos, Christos, et al.
Publicado: (2021)

Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion
por: Lutfi, Forat, et al.
Publicado: (2020)

Efficacy and Safety of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis
por: Gullapalli, Keerthi, et al.
Publicado: (2022)

Low molecular weight heparin and direct oral anticoagulants influence tumour formation, growth, invasion and vascularisation by separate mechanisms
por: Featherby, Sophie, et al.
Publicado: (2019)

Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism
por: Recio-Boiles, Alejandro, et al.
Publicado: (2019)

A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin
por: Tao, Ende, et al.
Publicado: (2020)

Is the Incidence Trend of Heparin-Induced Thrombocytopenia Decreased by the Increased Use of Low-Molecular-Weight-Heparin?
por: Al-Eidan, Fahad A S
Publicado: (2015)

Usage of Direct Acting Oral Anticoagulants in Cirrhotic and Non-Cirrhotic Portal Vein Thrombosis: A Systematic Review
por: Gupta, Sachin, et al.
Publicado: (2021)

Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation
por: Andrade, S.A., et al.
Publicado: (2012)

Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis
por: Wumaier, Kaidireyahan, et al.
Publicado: (2021)

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023)

Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome
por: Carré, Julie, et al.
Publicado: (2021)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

Non-Anticoagulant Activities of Low Molecular Weight Heparins—A Review
por: Feng, Ke, et al.
Publicado: (2023)

Secondary Immune Thrombocytopenia Due to Mycoplasma pneumoniae Without Clinically Significant Evidence of Active Infection
por: Park, Changsu L, et al.
Publicado: (2022)

Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar
por: Locke, Charles FS, et al.
Publicado: (2005)

Acute on Chronic Immune Thrombocytopenia as a Cause of Thrombocytopenia in Sepsis
por: Kudaravalli, Pujitha, et al.
Publicado: (2020)

Significance of Oral Manifestations in the Diagnosis of Severe Phenytoin-Induced Thrombocytopenia: A Rare Case
por: Gangadaran, Vinodh, et al.
Publicado: (2023)

Heparin-Induced Thrombocytopenia at the Emergency Department Due to Intermittent Heparin Flush in a Patient Undergoing Stem Cell Transplant
por: Thein, Kyaw Z, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ql7mq53ndlask7erfm6b30kk36